Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Therapeutic Targeting of Alzheimer's Disease with a Selective Antibody

90 views

Published on

Whiteboard2Boardroom presents innovations from regional universities, hospitals, research organizations to encourage commercialization.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Therapeutic Targeting of Alzheimer's Disease with a Selective Antibody

  1. 1. Therapeutic Targeting of Alzheimer's Disease with a Selective Antibody August 28, 2020
  2. 2. What is the problem? Desperate need for Alzheimer’s disease (AD) therapeutics AD Antibody – Passive Immunization Treatment for Alzheimer's Disease • AD is 100% fatal • No approved disease-modifying treatments • Current drugs only treat the symptoms of dementia – Oral regulators of acetylcholine (Aricept) or glutamate (Namenda)
  3. 3. What is the problem? Protein aggregation is at the core of AD AD Antibody – Passive Immunization Treatment for Alzheimer's Disease • Accumulation of aggregated amyloid-beta protein (Aβ) • Aβ senile plaques, oligomers and protofibrils Brain slice from AD patient Selkoe, Trends Cell Biol, 1998, 8, 447 Bitan et al., PNAS, 2003, 100, 330
  4. 4. How does product/service solve problem? Our solution is mAbSL antibody • Amyloid-β protein (Aβ) monoclonal antibody • We have obtained, cloned, sequenced, expressed, purified and characterized the monoclonal antibody – selectively targets a protofibril form of Aβ – given to early-stage AD patients – passive immunization treatment for AD Goure et al., Alzheimers Res Ther, 2014, 6, 42 mAbSL + +++ + (aducanumab) AD Antibody – Passive Immunization Treatment for Alzheimer's Disease
  5. 5. How does product/service solve problem? More on selectivity differences A42, ng/well 0 20 40 60 80 A450nm 0 1 2 protofibrils monomers fibrils ng A42, ng/well 0 20 40 60 80 A450nm 0 1 2 3 protofibrils monomers A B C(BAN2401) selective mAbSL113 non-selective mAbSL513 AD Antibody – Passive Immunization Treatment for Alzheimer's Disease
  6. 6. What is the market use? How will mAbSL be delivered? • Clinical diagnosis of early stage AD – mild cognitive impairment (MCI) and mild AD • In-patient intravenous delivery of monoclonal antibody solution • Monthly infusions • Measurement of cognitive improvement
  7. 7. What is the market use? Commercial potential of an AD therapy Early-stage AD (US) 10M MCI/mild cases $100M 1st year sales (10% of market) $1B after 5 years (market & case growth)
  8. 8. What competition exists? Drug Short-term dementia relief Stops AD progression Reverses AD effects Antibody selectivity Cholinesterase inhibitors Glutamate regulators Inflammation Tau Amyloid (Aβ) Aducanumab BAN2401 mAbSL Current trials Approved & prescribed AD Antibody – Passive Immunization Treatment for Alzheimer's Disease
  9. 9. What is the status of the intellectual property? • AMYLOID-BETA ANTIBODIES – University of Missouri-St. Louis – Patent application 62/889,220 (Filing date 8/20/2019) – Composition of Matter and Methods claims AD Antibody – Passive Immunization Treatment for Alzheimer's Disease
  10. 10. What is the stage of development? • Cloned and obtained the variable region DNA sequences for multiple selective and non-selective mAbSL antibodies • Developed methods for expression and purification of mAbSL antibodies AD Antibody – Passive Immunization Treatment for Alzheimer's Disease
  11. 11. Potential regulatory path for mAbSL • New Drug to pursue expedited Fast Track review • Clinical Trials, 5-7 years, early-stage AD, will seek pharma partnership – Phase 1 (safety, tolerability, immunogenicity, pharmacodynamics, pharmacokinetics), 50-100 participants – Phase 2 (clinical efficacy), 500-1000 participants – Phase 3 (efficacy, long-term safety, tolerability 1000-1500 participants • No approved comparable for AD • Average price for monoclonal antibody treatment is $96,000 (prices for oncology and hematology mAbs much higher) AD Antibody – Passive Immunization Treatment for Alzheimer's Disease
  12. 12. What is needed for further development? Research Milestones • Further research is needed to strengthen case that monoclonal AbSL antibody (mAbSL) is a potential AD disease-modifier 1. mAbSL production scale-up ($50K) 2. mAbSL effect in AD transgenic mice ($200K) a. diagnostics ability of mAbSL in control-treated AD mice b. prevention of pathology in mAbSL-treated AD mice (young) c. reversal of pathology in mAbSL-treated AD mice (aged) 3. humanize mAbSL antibody ($50K) AD Antibody – Passive Immunization Treatment for Alzheimer's Disease

×